Tiziana Life Sciences (TLSA) announces that the U.S. Food & Drug Administration, FDA, have approved the IND for its Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy, MSA. Multiple System Atrophy is an unmet medical need as there are currently no FDA approved therapies to treat this life limiting, orphan designated disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences initiated with a Buy at Lucid Capital
- Tiziana Life Sciences Unveils Promising Alzheimer’s Treatment Findings
- Tiziana Life announces immunologic analysis of nasal foralumab in AD patients
- Tiziana Life Sciences Expands Phase 2 MS Trial with New Site
- Tiziana Life Sciences expands Phase 2 intranasal foralumab trial with dosing